Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 3/2010

01-12-2010 | Research Report

Large neutral amino acids in daily practice

Author: Kirsten Kiær Ahring

Published in: Journal of Inherited Metabolic Disease | Special Issue 3/2010

Login to get access

Abstract

At the Kennedy Centre for Phenylketonuria, Denmark, large neutral amino acids (LNAAs) are being used to treat adult and adolescent patients who are nonadherent to dietary treatment for phenylketonuria (PKU). At the start of treatment, a patient must undergo dietary analysis and regular blood sampling to measure plasma amino acid (AA) concentrations. The aim of this analysis and treatment is that the patient receives 25–30% of the daily protein requirement from LNAA supplementation and the remaining 70–75% from natural, low-phenylalanine proteins (although some patients have difficulties in maintaining this level of protein intake). Patients are therefore able to follow a more “normal” diet than those adhering to a PKU diet with AA supplementation (in which only 20% of the daily protein requirement is provided from the diet and 80% from AA supplementation). LNAAs have also been used to treat older patients with untreated/late-diagnosed PKU who show profound intellectual, psychological, and behavioral impairments. Treatment with LNAAs has been shown to improve measures of concentration and awareness of external stimuli in some of these patients and thus enhance their socialization, emotionality, frustration tolerance, and mood.
Literature
go back to reference Andersen AE, Avins L (1976) Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria. Arch Neurol 33:684–686PubMedCrossRef Andersen AE, Avins L (1976) Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria. Arch Neurol 33:684–686PubMedCrossRef
go back to reference Giovannini M, Verduci E, Salvatici E, Fiori L, Riva E (2007) Phenylketonuria: dietary and therapeutic challenges. J Inherit Metab Dis 30:145–152PubMedCrossRef Giovannini M, Verduci E, Salvatici E, Fiori L, Riva E (2007) Phenylketonuria: dietary and therapeutic challenges. J Inherit Metab Dis 30:145–152PubMedCrossRef
go back to reference Güttler F, Lou H (1986) Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J Inherit Metab Dis 9(Suppl 2):169–177PubMedCrossRef Güttler F, Lou H (1986) Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J Inherit Metab Dis 9(Suppl 2):169–177PubMedCrossRef
go back to reference Güttler F, Wamberg E (1977) Fasting serum phenylalanine in untreated institutionalised patients with phenylketonuria. J Ment Defic Res 21:55–62PubMed Güttler F, Wamberg E (1977) Fasting serum phenylalanine in untreated institutionalised patients with phenylketonuria. J Ment Defic Res 21:55–62PubMed
go back to reference Kalkanoglu HS, Ahring KK, Sertkaya D et al (2005) Behavioural effects of phenylalanine-free amino acid tablet supplementation in intellectually disabled adults with untreated phenylketonuria. Acta Paediatr 94:1218–1222PubMedCrossRef Kalkanoglu HS, Ahring KK, Sertkaya D et al (2005) Behavioural effects of phenylalanine-free amino acid tablet supplementation in intellectually disabled adults with untreated phenylketonuria. Acta Paediatr 94:1218–1222PubMedCrossRef
go back to reference Lou H (1985) Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria. Lancet 2:150–151PubMedCrossRef Lou H (1985) Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria. Lancet 2:150–151PubMedCrossRef
go back to reference Lou HC, Lykkelund C, Gerdes AM, Udesen H, Bruhn P (1987) Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr Scand 76:560–565PubMedCrossRef Lou HC, Lykkelund C, Gerdes AM, Udesen H, Bruhn P (1987) Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr Scand 76:560–565PubMedCrossRef
go back to reference Matalon R, Michals-Matalon K, Bhatia G et al (2006) Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis 29:732–738, FFPubMedCrossRef Matalon R, Michals-Matalon K, Bhatia G et al (2006) Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis 29:732–738, FFPubMedCrossRef
go back to reference Pietz J, Kreis R, Rupp A et al (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103:1169–1178PubMedCrossRef Pietz J, Kreis R, Rupp A et al (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103:1169–1178PubMedCrossRef
go back to reference Scriver CR, Kaufman S (2001) Hyperphenylalaninemia:phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Childs B, Kinzler KW, Vogelstein B (assoc. eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, Chap. 77, pp 1667–1705 Scriver CR, Kaufman S (2001) Hyperphenylalaninemia:phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Childs B, Kinzler KW, Vogelstein B (assoc. eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, Chap. 77, pp 1667–1705
go back to reference Smith QR, Momma S, Aoyagi M, Rapoport SI (1987) Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem 49:1651–1658PubMedCrossRef Smith QR, Momma S, Aoyagi M, Rapoport SI (1987) Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem 49:1651–1658PubMedCrossRef
Metadata
Title
Large neutral amino acids in daily practice
Author
Kirsten Kiær Ahring
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue Special Issue 3/2010
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-010-9069-7

Other articles of this Special Issue 3/2010

Journal of Inherited Metabolic Disease 3/2010 Go to the issue